for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lumos Pharma Inc

LUMO.OQ

Latest Trade

6.84USD

Change

-0.31(-4.34%)

Volume

11,944

Today's Range

6.80

 - 

7.17

52 Week Range

6.80

 - 

36.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Lumos Pharma Reports Q3 2021 Financial Results

Nov 3 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES.QTRLY LOSS PER SHARE $0.90.Q3 EARNINGS PER SHARE VIEW $-1.07 -- REFINITIV IBES DATA.LUMOS PHARMA - CASH ON HAND AS OF END OF Q3 EXPECTED TO SUPPORT OPERATIONS THROUGH PRIMARY OUTCOME DATA READOUT FROM ORAGROWTH210 AND ORAGROWTH212 TRIALS.

Lumos Pharma Reports Second Quarter 2021 Financial Results And Provides Clinical And Corporate Updates

Aug 5 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL AND CORPORATE UPDATES.LUMOS PHARMA - CASH ON HAND AT Q2 END EXPECTED TO SUPPORT OPERATIONS THROUGH PRIMARY OUTCOME DATA READOUT FROM ORAGROWTH210 TRIAL IN H2 2023, ORAGROWTH212 TRIAL.LUMOS PHARMA INC QTRLY NET LOSS PER SHARE OF COMMON STOCK BASIC AND DILUTED $1.04.

Lumos Pharma Reports Qtrly Loss Per Share Of $1.04

May 5 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL AND CORPORATE UPDATES.QTRLY LOSS PER SHARE $1.04.Q1 EARNINGS PER SHARE VIEW $-0.87 -- REFINITIV IBES DATA.

Lumos Pharma Announces Retirement Of Carl Langren And Names Lori Lawley Chief Financial Officer In Planned Succession

April 20 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA ANNOUNCES RETIREMENT OF CARL LANGREN AND NAMES LORI LAWLEY CHIEF FINANCIAL OFFICER IN PLANNED SUCCESSION.LUMOS PHARMA INC - LORI LAWLEY WILL SUCCEED LANGREN AS CFO EFFECTIVE AS OF JULY 4, 2021.

Lumos Pharma Reports Full Year 2020 Financial Results

March 9 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA REPORTS FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES UPDATE ON ORAGROWTH TRIALS IN PGHD.LUMOS PHARMA - EXPECTS CASH ON HAND SUFFICIENT TO FUND CURRENT OPERATIONS THROUGH READ-OUT OF PHASE 2B ORAGROWTH210 TRIAL, COMPLETION OF ORAGROWTH212 TRIAL.

Lumos Pharma Reports Initiation Of Phase 2B OraGrowtH210 Trial

Nov 10 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA ANNOUNCES THE INITIATION OF PHASE 2B ORAGROWTH210 TRIAL AND REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS.LUMOS PHARMA INC - ANTICIPATES DATA READ OUT FOR ORAGROWTH210 TRIAL MID-YEAR 2022.LUMOS PHARMA - EXPECTS CASH ON HAND SUFFICIENT TO FUND CURRENT OPERATIONS THROUGH READ-OUT OF PHASE 2B ORAGROWTH210 TRIAL, COMPLETION OF ORAGROWTH212 TRIAL.

Lumos Pharma Reports Qtrly Loss Per Share $0.65

Aug 13 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA REPORTS SECOND QUARTER 2020 RESULTS AND PROVIDES UPDATE ON CLINICAL AND CORPORATE ACTIVITIES.LUMOS PHARMA INC - REAFFIRMS ITS EXPECTATION OF INITIATION OF ITS PHASE 2B LUM-201 TRIAL IN PEDIATRIC GROWTH HORMONE DEFICIENCY.LUMOS PHARMA INC - QTRLY LOSS PER SHARE $0.65.

Lumos Pharma Files For Resale Of Up To 4.15 Mln Shares

July 28 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA INC FILES FOR RESALE OF UP TO 4.15 MILLION SHARES OF COMMON STOCK SHELF BY SELLING STOCKHOLDERS - SEC FILING.

Lumos Pharma Files For Shelf Of Up To 4.15 Mln Shares By Selling Stockholders - SEC Filing

June 12 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA INC FILES FOR SHELF OF UP TO 4.15 MILLION MILLION SHARES BY SELLING STOCKHOLDERS - SEC FILING.

Lumos Pharma Reports Q1 Loss Per Share Of $0.14

May 28 (Reuters) - Lumos Pharma Inc <LUMO.O>::LUMOS PHARMA REPORTS FIRST QUARTER 2020 RESULTS AND PROVIDES UPDATE ON CLINICAL AND CORPORATE ACTIVITIES.LUMOS PHARMA- EXPECTS TO INITIATE ITS PHASE 2B LUM-201 TRIAL IN PEDIATRIC GROWTH HORMONE DEFICIENCY (PGHD) PRIOR TO END OF 2020.LUMOS PHARMA INC - ADDITIONAL NON-DILUTIVE FUNDS EXPECTED FROM ANTICIPATED MONETIZATION OF PRIORITY REVIEW VOUCHER (PRV).LUMOS PHARMA INC - CASH ON HAND EXPECTED TO FUND CURRENT OPERATIONS THROUGH PHASE 2B TRIAL READ-OUT.LUMOS PHARMA INC - CONTINUES TO PRIORITIZE CLINICAL DEVELOPMENT OF LUM-201.LUMOS PHARMA INC - NOW EXPECTS TO INITIATE PHASE 2B CLINICAL TRIAL IN PGHD PRIOR TO END OF 2020.LUMOS PHARMA INC - QTRLY LOSS PER SHARE $0.14.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up